SAR245409

DRUG5 trials

Sponsors

Sanofi, EMD Serono

Conditions

Chronic Lymphocytic LeukemiaIndolent Non-Hodgkin LymphomaLymphomaMantle Cell LymphomaNeoplasm MalignantOvarian Cancer

Phase 1

Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

CompletedNCT01410513

SanofiChronic Lymphocytic Leukemia, Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma

Start: 2011-12-31End: 2014-05-31Updated: 2016-04-01

Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen

CompletedNCT01587040

SanofiNeoplasm Malignant

Start: 2012-07-20End: 2018-05-23Updated: 2022-04-19

A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma

CompletedNCT01596270

SanofiNeoplasm Malignant

Start: 2012-06-30End: 2014-10-31Updated: 2020-10-28

Phase 2

A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia

CompletedNCT01403636

Start: 2011-10-31End: 2014-09-30Updated: 2016-03-17

Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer

CompletedNCT01936363

EMD SeronoOvarian Cancer

Start: 2013-09-30End: 2017-11-30Updated: 2018-12-12

Related Papers

Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.

2018-03-1446 citations

A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors.

2017-04-1713 citations

SAR245409 Monotherapy In Relapsed/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study

Blood2013-11-1510 citations